Teva Buys BioXcel Drug Assets for $57.5 Million

BioXcel Therapeutics completes the sale of its main drug assets as it moves toward winding down its business.

Updated on Nov. 2, 2026 in Healthcare

Plain amber glass bottles and clear vials on a brushed steel laboratory bench under cool daylight, with out-of-focus stainless equipment behind them. — Teva Pharmaceuticals acquired BioXcel Therapeutics' main drug assets, including rights to anti-agitation drug Igalmi, for $57.5 million on October 26 as BioXcel prepares to liquidate. AI Illustration. Upload story photo >

Live Poll

Do you trust large companies to treat workers fairly when they go bankrupt?

BioXcel Therapeutics completed a $57.5 million sale of its main drug assets, including rights to the anti-agitation drug Igalmi, to Teva Pharmaceuticals on October 26. The company, which filed for Chapter 11 bankruptcy protection in August, is preparing to wind down and liquidate.

Why it matters

The sale transfers Igalmi and related intellectual property to a larger drugmaker after years of losses and layoffs at the New Haven-based company. Proceeds are being used to repay loans that financed the bankruptcy process.

The upfront price is $57.5 million, with up to $67.5 million more tied to FDA approval of at-home Igalmi use and two $10 million payments at $250 million and $500 million in annual sales. The company reported 29 employees at the end of 2025, and whether the contingent payments will ever be triggered depends on regulatory approval not yet granted.

The players

BioXcel Therapeutics

A New Haven, Connecticut-based drug developer that focused on commercializing Igalmi, an anti-agitation treatment, before filing for bankruptcy.

Teva Pharmaceuticals

A large global generic and specialty drugmaker that acquired the rights to Igalmi and related BioXcel assets.

The details

The U.S. Bankruptcy Court in Delaware approved the sale on October 21. BioXcel terminated CEO Vimal Mehta, CFO Richard Steinhart, Chief Scientific Officer Frank Yocca and Chief Legal Officer Javier Rodriguez effective October 31, and Samir Saleem was appointed president and principal executive officer.

August 2026: BioXcel files for Chapter 11 bankruptcy protection.
October 21, 2026: Delaware bankruptcy court approves the sale.
October 26, 2026: Sale to Teva closes.
October 31, 2026: Four top executives are terminated.

Market Landscape

Small specialty drug developers in Chapter 11 have increasingly sold their commercial assets to larger pharmaceutical companies rather than continue independently. The BioXcel deal, which ties most of its value to future FDA approval and sales milestones, reflects how contingent structures are used to bridge uncertainty in such sales.

Patients who rely on Igalmi will depend on Teva's continued supply of the drug, but the status of at-home use depends on a pending FDA application that has not yet been approved. Any change to how the drug is marketed or priced under Teva will become clearer only after that regulatory decision.

The takeaway

Contingent payment structures tied to FDA approval let buyers share regulatory risk with sellers, which can make distressed drug assets saleable when upfront value alone is limited. For Connecticut readers, the case shows how a local biotech's fortunes can shift quickly when a bankruptcy court and a larger drugmaker take control of its core product.